GLYC
Price
$0.26
Change
+$0.01 (+4.00%)
Updated
Apr 25, 04:58 PM (EDT)
Capitalization
16.17M
6 days until earnings call
MDGL
Price
$326.79
Change
+$6.86 (+2.14%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
7.06B
6 days until earnings call
Ad is loading...

GLYC vs MDGL

Header iconGLYC vs MDGL Comparison
Open Charts GLYC vs MDGLBanner chart's image
GlycoMimetics
Price$0.26
Change+$0.01 (+4.00%)
Volume$423
Capitalization16.17M
Madrigal Pharmaceuticals
Price$326.79
Change+$6.86 (+2.14%)
Volume$31.56K
Capitalization7.06B
GLYC vs MDGL Comparison Chart
Loading...
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLYC vs. MDGL commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLYC is a StrongBuy and MDGL is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (GLYC: $0.25 vs. MDGL: $319.93)
Brand notoriety: GLYC and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLYC: 70% vs. MDGL: 69%
Market capitalization -- GLYC: $16.17M vs. MDGL: $7.06B
GLYC [@Biotechnology] is valued at $16.17M. MDGL’s [@Biotechnology] market capitalization is $7.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLYC’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • GLYC’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than GLYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLYC’s TA Score shows that 6 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).

  • GLYC’s TA Score: 6 bullish, 3 bearish.
  • MDGL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GLYC is a better buy in the short-term than MDGL.

Price Growth

GLYC (@Biotechnology) experienced а +12.42% price change this week, while MDGL (@Biotechnology) price change was +6.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.20%. For the same industry, the average monthly price growth was -4.19%, and the average quarterly price growth was -12.04%.

Reported Earning Dates

GLYC is expected to report earnings on Jul 30, 2025.

MDGL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.06B) has a higher market cap than GLYC($16.2M). MDGL YTD gains are higher at: 3.681 vs. GLYC (0.683). GLYC has higher annual earnings (EBITDA): -32.47M vs. MDGL (-450.12M). MDGL has more cash in the bank: 926M vs. GLYC (10.7M). GLYC has less debt than MDGL: GLYC (66.8K) vs MDGL (120M). MDGL has higher revenues than GLYC: MDGL (180M) vs GLYC (0).
GLYCMDGLGLYC / MDGL
Capitalization16.2M7.06B0%
EBITDA-32.47M-450.12M7%
Gain YTD0.6833.68119%
P/E RatioN/AN/A-
Revenue0180M-
Total Cash10.7M926M1%
Total Debt66.8K120M0%
FUNDAMENTALS RATINGS
GLYC vs MDGL: Fundamental Ratings
GLYC
MDGL
OUTLOOK RATING
1..100
3158
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
10029
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
6245
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (68) in the Pharmaceuticals Other industry is in the same range as GLYC (87) in the Biotechnology industry. This means that MDGL’s stock grew similarly to GLYC’s over the last 12 months.

MDGL's Profit vs Risk Rating (29) in the Pharmaceuticals Other industry is significantly better than the same rating for GLYC (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than GLYC’s over the last 12 months.

MDGL's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as GLYC (97) in the Biotechnology industry. This means that MDGL’s stock grew similarly to GLYC’s over the last 12 months.

MDGL's Price Growth Rating (45) in the Pharmaceuticals Other industry is in the same range as GLYC (62) in the Biotechnology industry. This means that MDGL’s stock grew similarly to GLYC’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as GLYC (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to GLYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLYCMDGL
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 19 days ago
86%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RCKY13.790.37
+2.76%
Rocky Brands
WBD8.500.17
+2.04%
Warner Bros Discovery
ZYME12.520.07
+0.56%
Zymeworks
ACLX63.970.34
+0.53%
Arcellx
ZAPP0.53-0.02
-3.02%
Zapp Electric Vehicles Group Limited

GLYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLYC has been closely correlated with LYRA. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLYC jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLYC
1D Price
Change %
GLYC100%
+5.03%
LYRA - GLYC
75%
Closely correlated
+7.02%
EYPT - GLYC
47%
Loosely correlated
-2.53%
AXON - GLYC
36%
Loosely correlated
+2.39%
IONS - GLYC
35%
Loosely correlated
+1.62%
MDGL - GLYC
34%
Loosely correlated
+3.61%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+3.61%
KANT - MDGL
62%
Loosely correlated
+38.53%
ALXO - MDGL
56%
Loosely correlated
+3.62%
ZNTL - MDGL
51%
Loosely correlated
+0.67%
CGEM - MDGL
50%
Loosely correlated
-2.86%
TSVT - MDGL
50%
Loosely correlated
N/A
More